Highlights•Ad vectors are highly immunogenic and thus superb vaccine carriers.•Most AAVs
are poorly immunogenic and thus more suited for gene replacement therapy.•Pre-existing …

Human adenoviral (HAd) vectors have demonstrated great potential as vaccine vectors.
Preclinical and clinical studies have demonstrated the feasibility of vector design, robust …

Adenoviral vectors are a safe and potently immunogenic vaccine delivery platform. Non-
replicating Ad vectors possess several attributes which make them attractive vaccines for …

Adenoviruses have transitioned from tools for gene replacement therapy to bona fide
vaccine delivery vehicles. They are attractive vaccine vectors as they induce both innate and …

One of the biggest challenges in optimizing viral vectors for gene therapy relates to the
immune response of the host. Adeno-associated virus (AAV) vectors are associated with low …

Adenoviruses are one of the most genetically diverse DNA viruses and cause non-
lifethreatening infections in the ocular, respiratory, or gastrointestinal epithelium of a diverse …

Since their discovery as a tool for gene transfer, vectors derived from the adeno-associated
virus (AAV) have been used for gene therapy applications and attracted scientist to this field …

Recombinant adeno-associated virus (rAAV) vectors have emerged as highly promising for
use in gene transfer for a variety of reasons, including lack of pathogenicity and wide host …

In recent years, the field of in vivo gene transfer with adenoassociated virus (AAV) vectors
has seen an extraordinary expansion of applications and investments. Results emerging …

Recombinant vectors based on adeno-associated virus (AAV) have been shown to stably
express many genes in vivo without mounting immune responses to vectors or transgenes …